Fundraising Fox
/Companies
Sign in

PathogenDx

Scottsdale, US · Founded 2015 · Delaware corporation · 3 known investors

Find your way into PathogenDx

Each arrow is one introduction. Sign up to fill in the first one.

667 people can intro you to Eric

Ask Chris Kastner to introduce you to Eric Lachance

You →Chris · together at Hii →Eric

76 people can intro you to Milan

Ask Jamie Chen to introduce you to Milan Patel

You →Jamie · together at University of Detroit Mercy →Milan

Sign up to find every way you can get introduced to PathogenDx

  • Your email: who you already know at PathogenDx, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the PathogenDx team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

PathogenDx provides molecular pathogen detection assays using proprietary D3 Technology for rapid, multiplexed identification of bacterial, fungal, and viral pathogens in food, agricultural, clinical, and environmental samples.

BiotechFoodTechMedical Devices

Founders & leadership

PathogenDx was founded in 2015 by Michael Hogan and Milan Patel.

MH
Michael HoganCSO
MPMilan Patel
Milan PatelCEO and Co-FounderMilan Patel has over twenty years of experience in corporate and entrepreneurial settings, ranging from small and mid-size businesses to Fortune 50 companies. He is CEO of PathogenDx, which provides molecular pathogen detection assays for rapid identification of bacterial, fungal, and viral pathogens in food, agricultural, clinical, and environmental samples.
ELEric Lachance
Eric LachanceCo-Founder and Board MemberHe has prior experience in defense, diagnostics, and power sectors, with expertise in supply chain management, emergency management, and operational planning.

Investors · 3

Altitude Investment Managementlisted by Altitude Investment Management

How we know: funding news · Not right? Tell us

Salveo Capitallisted by Salveo CapitalNorthbrook

Funding

SEC filings, press & company announcements

$11.6M disclosed across 3 rounds · 2016–2019

  • $7.5MSeries BSep 2019 · 2 sources
    Source ↗
  • $3.4MConvertible Note RoundJul 2018 · 2 sources
    Source ↗
▶$675KraisedApr 2016 · 4 investors · Biotechnology
Officers, directors & promoters on the filing
  • Eric LachanceExecutive Officer, Director
  • Michael HoganExecutive Officer, Director
  • Milan PatelExecutive Officer, Director
Offering amount
$1.2M
Amount sold
$675K
Minimum investment
$50K
First sale
Apr 2016
Incorporated
Corporation, Delaware, 2015
Federal exemptions
05
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 4

GendxGenDx develops molecular diagnostic reagents, software, and services for transplant patient outcomes. Operating globally since 2005, the company serves the healthcare and diagnostics industry with specialized tools for transplant diagnostics.
GenedxGeneDx provides advanced genetic testing and clinical interpretation services to help clinicians diagnose rare and inherited genetic disorders, with AI-driven genomic intelligence that supports patient care decisions and accelerates research and drug discovery.
CareDxCareDx provides innovative solutions and diagnostic tools for transplant patients throughout their pre- and post-transplant journey to improve outcomes and equity in organ transplantation.
MedicinalgenomicsMedicinal Genomics provides microbial and plant testing solutions for the cannabis, nutraceutical, and food safety industries through validated qPCR assays and automated liquid handling platforms. Their offerings enable rapid pathogen detection and species identification with turnaround times measured in hours rather than days.

Companies working in the same space as PathogenDx.

In the news

DNA-Based Pathogen Testing Company PathogenDx Raises $3.4 Million in Convertible Note Round - BioSpacebiospace.com · Jul 2018DNA-Based Pathogen Testing Company PathogenDx Raises $3.4 Million in Convertible Note Roundprnewswire.com · Jul 2018

Frequently asked questions

What does PathogenDx do?
PathogenDx provides molecular pathogen detection assays using proprietary D3 Technology for rapid, multiplexed identification of bacterial, fungal, and viral pathogens in food, agricultural, clinical, and environmental samples.
Who founded PathogenDx?
PathogenDx was founded by Michael Hogan, Milan Patel in 2015.
Who are PathogenDx's investors?
PathogenDx's investors include 7thirty, Altitude Investment Management, Salveo Capital.
How much funding has PathogenDx raised?
PathogenDx has disclosed $11.6M raised across 3 rounds.
Where is PathogenDx headquartered?
PathogenDx is headquartered in Scottsdale, US.